Treatment of antibody-mediated rejection

Research on treatment of antibody-mediated rejection after renal transplantation and prognosis of transplanted kidney

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1041240202

Enrollment

Registered

2025-03-13

Start date

2025-03-13

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Antibody-mediated rejection after kidney transplantation Antibody mediated rejection

Interventions

High-dose immunoglobulin intravenous infusion treatment covered by Japanese health insurance

D016756

IVIg

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: above 18 years old

Exclusion criteria

Exclusion criteria: less than 18 years old who refused to be included in this study

Design outcomes

Primary

Measure	Time frame
Changes in g, ptc, cg, ptcbm, cv, ci, ct scores at pre-treatment, post-treatment 3 months and 1 year	—

Secondary

Measure	Time frame
1. Change in renal function from before treatment 1-1. 30% decrease in eGFR 1-2. 30% increase in urinary protein (or 0.5 g/gCr or 1.0 g/gCr appearance) 2. Change in MFI from pre-treatment to 3 months and 1 year after treatment by LABScreen test 3. Graft survival	—

Contacts

Public ContactYuki Shimamoto

Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital

yukishimamot@nagoya2.jrc.or.jp+81-528321121

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026